{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:55:50Z","timestamp":1777895750562,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2026.e00843","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:33:58Z","timestamp":1770323638000},"page":"e00843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting dual specificity tyrosine-phosphorylation-regulated kinase 1A mitigates tauopathy and enhances recovery after repetitive head injury"],"prefix":"10.1016","volume":"23","author":[{"given":"Benoit","family":"Melchior","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie","family":"Browning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"McCartan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coral","family":"Hahn-Townsend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arissa","family":"Gratkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirta","family":"Grifman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Mouzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Pt 1","key":"10.1016\/j.neurot.2026.e00843_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/brain\/aws322","article-title":"Inflammation and white matter degeneration persist for years after a single traumatic brain injury","volume":"136","author":"Johnson","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2026.e00843_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-pathol-012615-044116","article-title":"Chronic traumatic encephalopathy: the neuropathological legacy of traumatic brain injury","volume":"11","author":"Hay","year":"2016","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00843_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1474-4422(17)30279-X","article-title":"The chronic and evolving neurological consequences of traumatic brain injury","volume":"16","author":"Wilson","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.26823","article-title":"Relative contributions of mixed pathologies to cognitive and functional symptoms in brain donors exposed to repetitive head impacts","volume":"95","author":"Saltiel","year":"2024","journal-title":"Ann Neurol"},{"issue":"0 3","key":"10.1016\/j.neurot.2026.e00843_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.expneurol.2015.06.015","article-title":"Polypathology and dementia after brain trauma: does brain injury trigger distinct neurodegenerative diseases, or should they be classified together as traumatic encephalopathy?","volume":"275","author":"Washington","year":"2016","journal-title":"Exp Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00843_bib6","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1474-4422(22)00309-X","article-title":"Traumatic brain injury: progress and challenges in prevention, clinical care, and research","volume":"21","author":"Maas","year":"2022","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00843_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094969","article-title":"The enigma of tau protein aggregation: mechanistic insights and future challenges","volume":"25","author":"Zheng","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"48","key":"10.1016\/j.neurot.2026.e00843_bib8","doi-asserted-by":"crossref","first-page":"34850","DOI":"10.1074\/jbc.M707358200","article-title":"DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease","volume":"282","author":"Ryoo","year":"2007","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00843_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/genes12111833","article-title":"Dyrk1a from gene function in development and physiology to dosage correction across life span in Down syndrome","volume":"12","author":"Atas-Ozcan","year":"2021","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nbd.2005.03.020","article-title":"Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models","volume":"20","author":"Ferrer","year":"2005","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00843_bib11","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1096\/fj.07-104539","article-title":"Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome","volume":"22","author":"Liu","year":"2008","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","article-title":"The role of DYRK1A in neurodegenerative diseases","volume":"278","author":"Wegiel","year":"2011","journal-title":"FEBS J"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00843_bib13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/acel.12648","article-title":"Dyrk1 inhibition improves Alzheimer's disease-like pathology","volume":"16","author":"Branca","year":"2017","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00843_bib14","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/s41598-018-20984-z","article-title":"DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives","volume":"8","author":"Neumann","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2026.e00843_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.nbd.2017.06.010","article-title":"Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes","volume":"106","author":"Garcia-Cerro","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00843_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41598-017-00682-y","article-title":"Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice","volume":"7","author":"Yin","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00843_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70172","article-title":"Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease","volume":"21","author":"Kac","year":"2025","journal-title":"Alzheimer's Dement"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.abb.2010.12.024","article-title":"Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)","volume":"507","author":"Adayev","year":"2011","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00843_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem J"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00843_bib20","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1111\/j.1742-4658.2009.07346.x","article-title":"Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation","volume":"276","author":"Gockler","year":"2009","journal-title":"FEBS J"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00843_bib21","doi-asserted-by":"crossref","first-page":"15648","DOI":"10.1021\/acs.jmedchem.3c01888","article-title":"Chemical, biochemical, cellular, and physiological characterization of Leucettinib-21, a Down syndrome and Alzheimer's disease drug candidate","volume":"66","author":"Lindberg","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2026.e00843_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117925","article-title":"A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD)","volume":"113","author":"Gehlot","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.neurot.2026.e00843_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115521","article-title":"Function and inhibition of DYRK1A: emerging roles of treating multiple human diseases","volume":"212","author":"Yang","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00843_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13000","article-title":"Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: a potential therapeutic for Alzheimer's disease","volume":"18","author":"Melchior","year":"2019","journal-title":"Aging Cell"},{"issue":"22","key":"10.1016\/j.neurot.2026.e00843_bib25","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1523\/JNEUROSCI.4637-04.2005","article-title":"Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms","volume":"25","author":"Andorfer","year":"2005","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00843_bib26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.1471-4159.2003.01879.x","article-title":"Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms","volume":"86","author":"Andorfer","year":"2003","journal-title":"J Neurochem"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00843_bib27","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1089\/neu.2012.2498","article-title":"Repetitive mild traumatic brain injury in a mouse model produces learning and memory deficits accompanied by histological changes","volume":"29","author":"Mouzon","year":"2012","journal-title":"J Neurotrauma"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.24064","article-title":"Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model","volume":"75","author":"Mouzon","year":"2014","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00843_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/acn3.510","article-title":"Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury","volume":"5","author":"Mouzon","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00843_bib30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnen\/nlw035","article-title":"Chronic repetitive mild traumatic brain injury results in reduced cerebral blood flow, axonal injury, gliosis, and increased T-Tau and tau oligomers","volume":"75","author":"Ojo","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00843_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneumeth.2011.09.003","article-title":"A mouse model of human repetitive mild traumatic brain injury","volume":"203","author":"Kane","year":"2012","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.neurot.2026.e00843_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.omtm.2023.04.002","article-title":"Human amnionic progenitor cell secretome mitigates the consequence of traumatic optic neuropathy in a mouse model","volume":"29","author":"McCartan","year":"2023","journal-title":"Mol Ther, Methods Clin Dev"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00843_bib33","doi-asserted-by":"crossref","first-page":"9340","DOI":"10.1523\/JNEUROSCI.22-21-09340.2002","article-title":"Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein","volume":"22","author":"Allen","year":"2002","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00843_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama","year":"2007","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00843_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrneurol.2013.29","article-title":"Chronic neuropathologies of single and repetitive TBI: substrates of dementia?","volume":"9","author":"Smith","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00702-016-1635-1","article-title":"Clustering of tau-immunoreactive pathology in chronic traumatic encephalopathy","volume":"124","author":"Armstrong","year":"2017","journal-title":"J Neural Transm"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/brain\/awx350","article-title":"Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model","volume":"141","author":"Tagge","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00843_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-021-00460-5","article-title":"\"Don't Phos Over Tau\": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies","volume":"16","author":"Xia","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/NEN.0b013e3182814cdf","article-title":"Repetitive mild traumatic brain injury augments tau pathology and glial activation in aged hTau mice","volume":"72","author":"Ojo","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2026.e00843_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1239653","article-title":"Traumatic brain injury and the pathways to cerebral tau accumulation","volume":"14","author":"Flavin","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00843_bib41","doi-asserted-by":"crossref","first-page":"fcz004","DOI":"10.1093\/braincomms\/fcz004","article-title":"Neurotoxic tau oligomers after single versus repetitive mild traumatic brain injury","volume":"1","author":"Bittar","year":"2019","journal-title":"Brain Commun"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23020064","article-title":"Indole-3-Carbonitriles as DYRK1A inhibitors by fragment-based drug design","volume":"23","author":"Meine","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.neurot.2026.e00843_bib43","first-page":"97","article-title":"Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities","volume":"11","author":"Lozano","year":"2015","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ebiom.2015.01.010","article-title":"DYRK1A-mediated cyclin D1 degradation in neural stem cells contributes to the neurogenic cortical defects in Down syndrome","volume":"2","author":"Najas","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neurot.2026.e00843_bib45","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.05920","article-title":"The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells","volume":"4","author":"Khor","year":"2015","journal-title":"eLife"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2026.e00843_bib46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: the devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00843_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40478-019-0678-6","article-title":"Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP\/PS1 mice","volume":"7","author":"Souchet","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e00843_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1200490","article-title":"Identifying promising GSK3beta inhibitors for cancer management: a computational pipeline combining virtual screening and molecular dynamics simulations","volume":"11","author":"Hua","year":"2023","journal-title":"Front Chem"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00843_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ph13020031","article-title":"Cell secretome: basic insights and therapeutic opportunities for CNS disorders","volume":"13","author":"Pinho","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00843_bib50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s13287-024-04107-2","article-title":"Exosome-based therapies for inflammatory disorders: a review of recent advances","volume":"15","author":"Saleem","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00843_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12081836","article-title":"P-tau217 as a reliable blood-based marker of Alzheimer's disease","volume":"12","author":"Lai","year":"2024","journal-title":"Biomedicines"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:01:41Z","timestamp":1777622501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747926000139"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00843","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting dual specificity tyrosine-phosphorylation-regulated kinase 1A mitigates tauopathy and enhances recovery after repetitive head injury","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00843"}}